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Introduction. First Nations and other Aboriginal children are disproportionately affected by cardiometabolic
diseases, including type 2 diabetes (T2D). In T2D, the disruption of insulin signalling can be driven by pro-
inflammatory immunity. Pro-inflammatory responses can be fueled by toll-like receptors (TLR) on immune
cells such as peripheral blood mononuclear cells (PBMC, a white blood cell population). TLR4 can bind to
lipids from bacteria and food sources activating PBMC to produce cytokines tumour necrosis factor (TNF)-a
and interleukin (IL)-1b. These cytokines can interferewith insulin signalling. Here, we seek to understand how
TLR4 activation may be involved in earlyonset T2D. We hypothesized that immune cells fromyouth with T2D
(n 8) would be more reactive upon TLR4 stimulation relative to cells from age and body mass index (BMI)-
matched controls without T2D (n 8).
Methods. Serum samples were assayed for adipokines (adiponectin and leptin), as well as cytokines. Freshly
isolated PBMC were examined for immune reactivity upon culture with TLR4 ligands bacterial
lipopolysaccharide (LPS, 2 and 0.2 ng/ml) and the fatty acid palmitate (200 mM). Culture supernatants
were evaluated for the amount of TNF-a and IL-1b produced by PBMC.
Results. Youth with T2D displayed lower median serum adiponectin levels compared to controls (395 vs. 904
ng/ml, pB0.05). PBMC isolated from youth with and without T2D produced similar levels of TNF-a and IL-
1b after exposure to the higher LPS concentration. However, at the low LPS dose the T2D cohort exhibited
enhanced IL-1b synthesis relative to the control cohort. Additionally, exposure to palmitate resulted in greater
IL-1b synthesis in PBMCs isolated from youth with T2D versus controls (pB0.05). These differences in
cytokine production corresponded to greater monocyte activation in the T2D cohort.
Conclusion. These preliminary results suggest that cellular immune responses are exaggerated in T2D,
particularly with respect to IL-1b activity. These studies aim to improve the understanding of the biology
behind early onset T2D and its vascular complications that burden First Nations people.
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M
etabolic syndrome (MetS) and type 2 diabetes
(T2D)presentasignificantburdentoCanadian
First Nations and other Indigenous popula-
tions (1). More troubling is that these metabolic diseases,
which were once restricted to adults, are becoming increa-
singly prevalentin children andyouth (2). Within Canada,
Manitoba has the highest incidence of early onset T2D,
with First Nations being disproportionately affected (3,4).
The increasing prevalence of T2D among Indigenous
youth worldwide can be attributed to both genetic and
environmental factors (5,6). Significant environmental
changes include a shift away from traditional food to
nutrient sparse, calorie dense, westernized food, as well as
an increasing sedentary lifestyle. The shift away from a
more traditional lifestyle is reflected in the considerable
ratesofobesitywithinFirstNationsyouthinCanada(7,8).
Obesity is a significant determinant of MetS and T2D
(9,10). In one First Nations community, obese children
hada5.1oddsratio(95%CI1.51,17.0)ofdevelopingT2D
before the age of 18 years (11).
Adipose tissue as immune tissue in T2D
The immune system is a critical mediator in the onset of
T2D. Adipose tissue is not inert, but acts as inflammatory
immune tissue. Adipose tissue consists of adipocytes that
secrete adipokines or ‘‘fat hormones’’such as apidonectin
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insulin sensitivity and therefore play a role in maintaining
normal glucose levels. Adiponectin levels are decreased in
states of metabolic disease; whereas, leptin concentrations
are often increased (12,13). However, the role of adipo-
kines in the natural history of early onset T2D is poorly
understood.
Toll-like receptor 4 and sterile inflammation
Adipose tissue also contains macrophages, which can
account for more than 25% of cells within the adipose
tissue(14).Whenmacrophagesmoveintothebloodstream
they take on different characteristics and are called mono-
cytes.Macrophage/monocytes interactwithlipidsthrough
receptors on their surface including toll-like receptor
(TLR)4. TLR4 is important in protecting the body from
bacterial infections through binding lipopolysaccharides
(LPS)foundonthesurfaceofGram-negativebacteriasuch
as E. coli. The binding of TLR4 to LPS in a bacterial
infection results in the macrophages/monocytes becoming
activated allowing them to produce pro-inflammatory
cytokines, which assist in clearing the infections. However,
chronic exposure to these cytokines can be harmful.
Chronic cytokine exposure can occur upon consump-
tion of diets high in lipids. These lipid complexes can also
bind TLR4 receptors causing cells to become activated.
Palmitate is a fatty acid that is present in many foods.
Increased serum palmitate levels are associated with a
high degree of liver steatosis (15). In addition, palmitate
exposure can increase TLR4 levels on macrophage cell
lines 8-fold, as well as activate TLR4 resulting in pro-
inflammatory cytokine production (16). Similar findings
were observed with human monocytes (16).
Cytokines in T2D
Many cytokines have been implicated in obesity-induced
inflammation and T2D. Our focus has been on tumour
necrosis factor (TNF)-a, interleukin (IL)-1b and IL-6.
These cytokines can impair insulin signalling or induce
b-cell apoptosis (17 19). However, it is only in cases of
extreme immune activation that cytokine spillage into the
blood stream occurs. Thus, examination of TLR4 respon-
siveness requires an assessment of cellular activity.
Immunity in Manitoban Indigenous populations
TLR4 activation can upset the normal balance of the
immune system promoting insulin resistance. This
can lead to an increased risk for cardiovascular and
other diseases (20 22). The relevance of TLR4-induced
cytokine activity in early onset diabetes in Aboriginal
peoples is unknown. Serological studies, examining im-
mune markers in the serum have had limited findings
(23). However, previous studies by our unit and others
indicated a marked difference in immune genetics be-
tween Manitoban Indigenous peoples and Caucasians
(5,6,24). An assessment of cellular immune function,
examining peripheral blood mononuclear cell (PBMC)
cytokine production, also indicated that First Na-
tions adults have greater inflammatory responses than
Caucasians (5).
The heightened pro-inflammatory immunity observed
in these studies, concomitant with stressful environments
and changes in lifestyle, could promote an earlier onset of
T2D. Altogether, these factors could enhance sus-
ceptibility to, and progression of, T2D, as well as pro-
mote the high prevalence of T2D-related co-morbidities
observed in this young population (25 27).
Study goal
The purpose of this study is to evaluate systemic
(evaluated in serum) and cellular (examined with
PBMC) immunity in youth with T2D relative to age-
and body mass index (BMI)-matched normoglycemic
youth to determine the role of the immune system in
earlyonset T2D. We hypothesized that immune cells from
youth with T2D would be more reactive upon TLR4
stimulation compared to PBMC from youth without
T2D.
Methods
Subjects
This study was approved by the University of Manitoba
Research Ethics Board and Health Sciences Centre
(HSC) Research Board, Winnipeg, Manitoba. In addition
to ethical approvals, progress reports were presented to
the Manitoba First Nation Diabetes Committee, an
advisory committee of individuals who work in Manito-
ban First Nations communities, which is funded by the
diabetes programme of the First Nations and Inuit Health
Branch of Health Canada. Youth with T2D were
recruited through the paediatric endocrinology clinic,
Winnipeg Children’s Hospital, Winnipeg, MB. Over-
weight youth without T2D were recruited through the
Manitoba Institute of Child Health, a research unit
serving a large geographic region of central Canada.
Youth (14 18 yrs old) qualifying for the study were
approached by a clinical research coordinator. Written
informed consent was given by parents or guardians.
Participants provided a signature of assent to state
agreement to their involvement. A short questionnaire
inquiring about general health, co-morbidities and med-
ications was also administered. Ethnicity was self-
declared as First Nations or Me ´tis. All other groups
were designated as non-Aboriginal.
Individuals with chronic infections, chronic inflamma-
tory disease and/or signs of acute infection (cold, flu,
malaise) were not recruited. We also excluded individuals
with the known hepatic nuclear factor (HNF)-1a G319S
polymorphism (GS or SS genotype). The HNF-1a G319S
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T2D in the Oji-Cree First Nations population in Man-
itoba and northwestern Ontario. It results in a mild
insulin secretory defect and is associated with early onset
T2D in this population (28,29).
Clinical parameters
Participants were weighed in kilograms using a standard
office scale. Height (in centimetres) was assessed using a
stadiometer. BMI was computed from height and weight
(height/m
2). Obesity was defined as]95 percentile for
age and gender (30). Blood pressure was measured in the
sitting position using a standard sphygmomanometer.
Clinical chemistry was determined at the Clinical Chem-
istry Department, HSC.
Blood sample collection and PBMC isolation
Serum samples and whole blood were collected in the
morning. Serum samples were stored at  808Cu n t i l
analysis of cytokines by ELISA. ELISAs were performed
as previously described (31). Adiponectin and leptin
ELISAs were purchased from R&D Systems (Minnea-
polis, MN, USA).
PBMC are a white blood subset containing monocytes
and lymphocytic cells including T cells and B cells.
PBMC were isolated from whole blood with Ficoll
(Sigma, St. Louis, MO, USA) as previous described
(5,31). Cells consistently exhibited 98% viability (5,31).
In vitro culture and cytokine protein analysis
Freshly isolated PBMC were cultured at 0.25 10
6 cells/
ml in 96-well round bottom plates (Corning Inc.,
Corning, NY, USA) and incubated with culture medium,
TLR4 ligands LPS (2 and 0.2 ng/ml, Sigma) or palmitate
(200 mM, Sigma) conjugated to bovine serum albumin.
Palmitate was conjugated as previously described (16).
Supernatants were harvested 24 hours later for the
detection of cytokine levels.
Intracellular cytokine staining
Briefly, freshly isolated PBMC were cultured (0.25 10
6
cells/well) in the presence of medium, LPS (20 ng/ml) or
palmitate(200mM)alongwithBrefeldineA(10mg/ml,BD
Biosciences) for 4 hours. Brefeldine A inhibits secretion
of protein from cells. At 4 hours, cells were washed.
Fluorochrome-conjugated anti-CD14, an antibody that
detects monocytes, was added for 30 minutes at 48C. Cells
were washed with 0.01% saponin solution to permeablize
the cells so that the antibodies could penetrate the cell
membrane. Fluorochrome-conjugated antibodies for in-
tracellular staining against TNF-a and IL-1b were added
for 30minutesin thedark.Cellswerewashedandstored at
48C in the dark. The next day, the datawere acquired on a
BD FACSCanto II flow cytometer. This machine allows
visualization of the fluorochromes so that the percentage
of cells bound by corresponding antibodies can be
assessed.
Data analysis
Categorical differences were determined by x
2 Fisher’s
exact test. The Mann-Whitney test was used to determine
if significant differences existed between the presence
and absence of T2D. Spearman’s correlation was used to
determine relationships between immune and clinical
parameters. pB0.05 was considered significant.
Results
Patient demographics
This preliminary report details findings from youth with
(n 8) and without (n 8) T2D. Demographic profiles
were similar, except that the T2D cohort contained a
greater percentage of First Nations youth relative to the
non-T2D cohort (pB0.05, Table I). Youth with T2D also
displayed slightly higher resting systolic blood pressure
(pB0.05).
Adiponectin levels were lower in early onset T2D
Adiponectin concentrations were lower in the T2D
cohort relative to the control cohort (pB0.01, Fig. 1);
whereas leptin levels were similar between the groups.
Leptin levels, however, positively correlated with BMI
(pB0.01). Circulating TNF-a and IL-6 levels, an indica-
tion of systemic immune activation, were undetectable in
these youth cohorts.
Table I. Study cohorts
Parameters T2D
b (n 8) Control (n 8)
Demographics
Age (years)
a 15 (15 17) 16 (14 17)
Female (%) 87.7 75
First Nation (%) 87.5 25*
Me ´tis (%) 0 25
Non-Aboriginal (%) 12.5 50
Clinical and laboratory
BMI
a 27 (22.2 42.2) 29 (25.1 38.7)
Blood pressure
a
Systolic (mmHg)
a 129 (105 139) 106 (102 136)*
Diastolic (mmHg)
a 67 (57 84) 64 (53 74)
Triglyceride (mmol/L)
a 1.6 (0.6 3.5) 2.0 (1 3.4)
ALT (IU/l)
a 20.0 (10 46) 14.0 (11 46)
AST (IU/l)
a 21.5 (11 31) 20.0 (13 33)
aMedian and range shown.
bQuantitative data were assessed by Mann Whitney. Categorical
differences were determined by x
2 Fisher’s exact test. *pB0.05
was considered significant. BMI, body mass index; ALT, alanine
aminotransferase; AST, aspartate aminotransferase.
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youth with and without T2D
To assess whether sensitivity to TLR4 activation in T2D
and obese youth cohorts differed, PBMC were incubated
with culture medium, LPS (2 or 0.2 mg/ml) or palmitate.
Independent of LPS or palmitate stimulation TNF-a
production was comparable between T2D and control
cohorts(Fig.2A).IL-1bsecretionwasalsosimilarbetween
cohorts at the high LPS concentrations. In contrast, at the
low LPS dose PBMC from the T2D cohort were more
reactive for IL-1b synthesis than cells acquired from obese
youth without T2D (medians, 1,745 vs. 705 pg/ml,
pB0.05). Moreover, following palmitate activation
PBMC secretion of IL-1b was 3.5-fold greater from the
T2D cohort relative to their counterparts (medians, 2,927
vs. 849 pg/ml, pB0.05). TNF-a and IL-1b synthesis did
not correlate with clinical parameters (data not shown).
PBMC consist of monocyte and lymphocyte popula-
tions. Because of their putative role in T2D, monocyte
reactivitytoLPSandpalmitatewasdirectlyexaminedwith
intracellular cytokine staining. A greater percentage of
monocytes from the T2D cohort (n 3) were actively
producing TNF-a and IL-1b in response to TLR4 activa-
tion by LPS than from monocytes from the control cohort
(n 3, Fig. 2B). Palmitate exposure for 4 hours also
resulted in a greater percentage of monocytes from
youth with T2D than youth without T2D being involved
in TNF-a and IL-1b synthesis.
Discussion
Inflammatory immunity stemming from adipose tissue is
a critical factor in the onset and progression of T2D in
adult human and animal models. The primary novel
finding from this preliminary cross sectional study of
immune reactivity in early onset T2D was that the
immune response from youth with T2D was hyperreac-
tive to long chain fatty acids compared to obese matched
youth without T2D.
Adipokines
Adiponectin levels are lower among overweight indivi-
duals with metabolic diseases, in particular dysglycemia
(32 35). The data presented here extend these findings by
demonstrating that adiponectin concentrations were also
lower in youth with T2D compared to normoglycemic
Fig. 1. Adipokine associations with disease parameters. Serum adiponectin and leptin concentrations were assessed by ELISA. A.
Adiponectin levels were signiﬁcantly lower in T2D youth, compared to obese matched controls. Horizontal bars indicate median values
(Mann-Whitney, *pB0.05). B. Leptin concentrations correlated with BMI. Relationships were assessed by Spearman correlation
(**pB0.01). Serum samples were also analyzed for cytokines TNF-a and IL-6 based on previous studies by group members. However,
serum cytokines were undetectable in these subjects (data not shown).
Julia D. Rempel et al.
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revealed that adiponectin levels are prognostic for
(23,36). Whether hypoadiponectinemia is a cause or
consequence of dysglycermia in youth has yet to be
determined. Prospective cohort studies of obese youth
are needed to determine its role in the natural history of
early onset T2D.
Systemic immunity
Systemic immunity reflects the background inflammatory
status of the body, representing the ‘‘spill over’’ from
cellular events. In adults, serum pro-inflammatory cyto-
kines such as TNF-a and IL-6 are elevated in those with
obesity and T2D relative to healthy controls (37). Here,
serum TNF-a and IL-6 were undetectable. The absence of
serum cytokines, a common finding in obese adults
suggests that the duration of T2D affects the extent of
systemic inflammation. In a study of 362 children, low
serum TNF-a levels did not correlate with metabolic
syndrome or BMI (38). However, associations of pro-
inflammatory cytokines with obesity in adolescents have
been observed (33). Stringer et al. also found that serum
IL-6, but not TNF-a, levels were higher in T2D (n 24)
relative to obese matched (n 19) First Nations youth
(23). The difference between the results of these studies is
unclear. Both studies have a small sample size and
different individual subjects.
Cellular immunity
In addition, the susceptibility of PBMC to TLR4
activation was examined by culturing freshly isolated
PBMC with LPS and palmitate. LPS- or palmitate-
induced TNF-a did not differentiate with T2D diagnosis
(Fig. 2A). Similar results were observed for IL-1b
production upon activation with the higher LPS dose.
However, at the low LPS dose (0.2 mg/ml), the cells
Fig. 2. T2D cohort demonstrates enhanced cellular sensitivity to TLR4 ligands than obese controls. A. PBMC from youth with (n 8,
grey bars) and without (n 8, white bars) T2D were cultured as described in Methods. Whisker plots show medians and ranges (Mann
Whitney, *pB0.05). B. PBMC from youth with (n 3) and without T2D (n 3) were activated for 4 hrs with LPS and palmitate. Cells
were stained as per Methods (ICCS). Shown are PBMC gated on the CD14 positive cells, the monocyte population. Red lines indicate
responses to culture medium alone. Blue lines indicate responses to either LPS or palmitate as indicated. One set of 3 representative
results is shown.
Immune activation in type 2 diabetes
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1b than their counterparts (pB0.05). Thus, in early onset
T2D, peripheral immune cells appear to have a lower
threshold for LPS-induced IL-1b synthesis. Moreover,
palmitate activation induced higher median levels of IL-
1b from the T2D cohort versus the obese control cohort
(2,927 vs. 849 pg/ml, pB0.05). This indicates that in early
onset T2D, PBMC are more sensitive to low doses of the
TLR4 activator LPS, as well as the fatty acid palmitate.
Thus, it may be that the consumption of even low levels
of lipids cause a greater inflammatory reaction for
individuals with T2D than for obese individuals without
T2D.
PBMC consist of monocytes and lymphocytes. Macro-
phage/monocyte populations are key producers of pro-
inflammatory cytokines (39). Here, monocyte behaviour
in early onset T2D (n 3) relative to obese controls
(n 3) was examined (Fig. 2B). Independent of TLR4
activator, the percentage of monocytes producing TNF-a
and IL-1b was greater for the T2D cohort relative to the
cohort without T2D. The difference in TNF-a activity
observed between the PBMC cultures (24 hour) and the
intracellular assays (4 hour) may suggest that initially
monocytes are more reactive with respect to TNF-a
production but level out with time. Although within a 4-
hour culture monocytes are the primary source of LPS-
and palmitate-induced TNF-a and IL-1b production
(data not shown), the response of other cells within the
PBMC may eventually dilute out the initial differences in
monocyte activity. The greater reactivity of monocytes
for IL-1b synthesis supports the findings with PBMC 24-
hour cultures, suggesting that the IL-1b response is more
sustained.
Cytokine activity
This dichotomy in TNF-a and IL-1b activity may reflect
physiological differences between obese states relative to
T2D. TNF-a has been implicated in the pathology
underlying obesity and T2D. Nonetheless, there is
inadequate information on PBMC TNF-a production
in obesity or the metabolic syndrome in adults. Much less
is known in paediatric populations (40). TNF-a-mediated
processes may be more involved in the complications
associated with T2D such as cardiovascular disease
(41,42). Conversely, IL-1b is considered an instigator of
metabolic disease due to its capacity to drive sterile
inflammation (43). Extensive studies in humans and
animal have found that IL-1b, or inflammasome compo-
nents required for the secretion of IL-1b, are increased in
metabolic disease (reviewed in Refs. 44,45). Moreover,
treatment with IL-1b antagonists can improve glycaemia
in adults with T2D and in animal models of T2D (46,47).
Here, IL-1b levels did not correlate with physical para-
meters or clinical chemistry, but this may be due to the
small sample size. The narrow BMI range may also have
limited analysis of immune activity with respect to BMI.
Study limitations
First, the sample size was small raising the likelihood
of type 1 or 2 errors in the statistical analysis. This is
particularly the case with the intracellular cytokine stain-
ing. Second, there were significantly more First Nations
individuals in the T2D cohort compared to controls,
making it possible that this was an effect based on ethnic
differences in immunity. However, when analyzed against
ethnicity IL-1b production after exposure to LPS or
palmitate did not differ between First Nations and non-
First Nations individuals (data not shown). In addition,
IL-1b synthesis by PBMC from First Nations with T2D
(n 7) was 3- and 4-fold greater than that from First
Nations without T2D (n 2) following culture of cells
with LPS (0.2 mg/ml) and palmitate, respectively (data
not shown). Taken together, this supports the premise
that the difference in IL-1b activity is due to the presence
of T2D and not due to differences in ethnicity. Finally,
the exact relationship between the behaviourof peripheral
PBMC or monocytes and adipose tissue macrophages
remains to be determined.
Summary
Indigenous people appear to have a greater pro-inflam-
matory physiology likely reflecting environmental gene
interactions (5,6,24). Due to the greater incidence of
early onset metabolic disease in First Nations and other
Indigenous populations, we were interested in determin-
ing the immune events associated with early onset T2D.
Taken together, these initial findings suggest that certain
immunological parameters are common in obese youth
independent of T2D. PBMC-induced TNF-a synthesis,
for example, did not differ between obese adolescents
with and without T2D. However, it appears that in early
onset T2D, there is a greater susceptibility to IL-1b
synthesis upon exposure to low levels of LPS or the fatty
acid palmitate. Thus, there may be no safe amount of
certain lipid complexes for individuals with T2D to
consume.
We are continuing to evaluate systemic and cellular
immunity inearlyonsetT2D,inconjunctionwithage-and
BMI-matched controls. T2D presents a serious burden to
the First Nations community. The goal of our studies is
an improved understanding of the biology behind T2D in
First Nations children in support of new therapeutics in
the prevention of T2D and related complications.
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